Market research
STSA Satsuma Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 37M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- 0.0%
- Beta
- 0.1
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US80405P1075
- Market cap
- 37M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- 0.0%
- Beta
- 0.1
About
About Satsuma Pharmaceuticals Inc
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company's product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the STSA discussion.
5 years, 4 months ago
Satsuma Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 28.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Satsuma Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.6% to $-48K since the same quarter in the previous year.
Finally, its free cash flow fell by 79.0% to $-13M since the same quarter in the previous year.
Based on the above factors, Satsuma Pharmaceuticals, Inc gets an overall score of 3/5.